Bionano Genomics, Inc.
BNGO
$1.14
-$0.02-1.72%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -7.37% | -13.84% | -25.02% | -24.04% | -14.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.37% | -13.84% | -25.02% | -24.04% | -14.79% |
| Cost of Revenue | -49.59% | -54.27% | 0.22% | 3.02% | 14.48% |
| Gross Profit | 3,369.47% | 2,304.01% | -86.92% | -95.21% | -96.03% |
| SG&A Expenses | -33.04% | -36.02% | -48.63% | -53.81% | -45.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.57% | -48.42% | -45.45% | -47.97% | -39.00% |
| Operating Income | 56.66% | 60.77% | 52.45% | 54.87% | 45.23% |
| Income Before Tax | 76.49% | 71.61% | 63.60% | 63.12% | 51.82% |
| Income Tax Expenses | 100.00% | 900.00% | 281.82% | 222.22% | -46.77% |
| Earnings from Continuing Operations | 76.44% | 71.58% | 63.58% | 63.10% | 51.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 76.44% | 71.58% | 63.58% | 63.10% | 51.82% |
| EBIT | 56.66% | 60.77% | 52.45% | 54.87% | 45.23% |
| EBITDA | 62.14% | 65.40% | 59.47% | 61.17% | 50.37% |
| EPS Basic | 94.10% | 88.48% | 85.03% | 84.09% | 77.07% |
| Normalized Basic EPS | 92.29% | 90.78% | 85.00% | 82.35% | 74.34% |
| EPS Diluted | 94.10% | 88.48% | 85.03% | 84.09% | 77.08% |
| Normalized Diluted EPS | 92.29% | 90.78% | 85.00% | 82.35% | 74.34% |
| Average Basic Shares Outstanding | 328.30% | 220.00% | 183.26% | 160.16% | 123.34% |
| Average Diluted Shares Outstanding | 328.30% | 220.00% | 183.26% | 160.16% | 123.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |